Skip to Main Content

Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS) have both developed effective treatments for a rare nerve disorder known as familial amyloid polyneuropathy (FAP). Which drug is better? Dueling clinical trial presentations made Thursday at a research meeting in Paris gave investors a unique opportunity to compare.

The winner: Alnylam.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!